News Breaks |
|
|
| February 11, 2013 |
| 16:02 EDT |  | MNKD | MannKind reports Q4 EPS (23c) , consensus (18c)
|
|
|
News For MNKD From The Last 14 Days Check below for free stories on MNKD the last two weeks. |
|
|
| May 23, 2013 |
| 16:00 EDT |  | MNKD | Options Update; May 23, 2013
 Subscribe for More Information |
|
| 11:24 EDT | | MNKD | High option volume stocks: ZTS AMLP CTAS MNKD CYS
Subscribe for More Information |
|
| 09:59 EDT |  | MNKD | MannKind bucks general market downdraft, but falls from early highs
The stock was up sharply to $6.82, a new 52-week high, but has since fallen to $6.33. At that price, next support is at $6.23, the prior day close, and then at $6.05. Resistance is now at $6.54, the prior day high. |
|
| 05:49 EDT | | MNKD | Stocks with implied volatility movement; MNKD ORCL
Stocks with implied volatility movement; MannKind (MNKD), Oracle (ORCL) according to IVolatility. |
|
| May 22, 2013 |
| 16:00 EDT | | MNKD | Options Update; May 22, 2013
Subscribe for More Information |
|
| 11:50 EDT | | MNKD | High option volume stocks: ZTS AIRM GLDD GTXI MNKD
Subscribe for More Information |
|
| 11:46 EDT | | MNKD | MannKind volatility elevated on sharp rally to 28-month high
Subscribe for More Information |
|
| May 17, 2013 |
| 10:25 EDT |  | MNKD | Summer Street says more optimistic on MannKind approval
Summer Street says it is more optimistic that the current trials of MannKind's inhalable insulin Afrezza could lead to FDA approval. The firm notes the product is completing two phase III trials and that it has been skeptical of approval in the past. Summer Street does not have an official rating on shares of MannKind, which are up 22c to $5.38 in early trading. |
|
|
|
|
|
